$141.00
Manufacturer: Ireland
Adjuvant therapy in women with invasive early-stage breast cancer with a positive test for estrogen receptors in the postmenopausal period after 2-3 yEars and Nose of initial adjuvant therapy with tamoxifen.
Treatment of advanced breast cancer in women with natural or induced postmenopausal status who have been diagnosed with disease progression after antiestrogen therapy. No efficacy was demonstrated in patients with a negative test for estrogen receptors.
Description
Exemestane Grindex Composition
active substance: exemestane;
1 tablet contains 25 mg of exemestane;
excipients: mannitol (E 421), copovidone (type A), crospovidone (type A), microcrystalline cellulose, sodium starch glycolate (type A), magnesium stearate;
shell: hypromellose, macrogol 400, titanium dioxide (E 171).
Exemestane Grindex Dosage form.
Film-coated tablets.
Basic physical and chemical properties: round biconvex tablets, film-coated, white or yellowish, engraved with “25” on one side and with a smooth surface on the other side.
Pharmacotherapeutic group.
Hormone antagonists and similar agents. Aromatase inhibitors.
ATX code L02B G06
Exemestane Grindex Pharmacological properties
Pharmacodynamics.
Exemestane is an irreversible steroidal aromatase inhibitor, similar in chemical structure to the natural substance androstenedione. In postmenopausal women, estrogens are produced primarily by converting androgens to estrogens under the action of the aromatase enzyme in peripheral tissues. Blocking estrogen production by inhibiting aromatase is an effective and selective treatment for hormone-dependent breast cancer in postmenopausal women.
In postmenopausal women, exemestane significantly reduces serum estrogen concentrations, starting at a dose of 5 mg; the maximum reduction (> 90%) is achieved with a dose of 10–25 mg. In postmenopausal women diagnosed with breast cancer who received the drug at a dose of 25 mg / day daily, the total level of aromatase decreased by 98%.
Exemestane has no progestogenic and estrogenic activity. Insignificant androgenic activity, probably associated with 17-hydroderivate, was noted mainly when using the drug in high doses. In studies, prolonged daily intake of exemestane did not affect the synthesis of hormones such as cortisol and aldosterone, the levels of which changed before or after the test with adrenocorticotropic hormone; this demonstrated selectivity with respect to other enzymes involved in hormonal metabolism. In this regard, there is no need for replacement therapy with glucocorticoids and mineralocorticoids.
Indications
Adjuvant therapy in postmenopausal women with early-stage invasive breast cancer with a positive test for estrogen receptors after 2-3 years of initial adjuvant tamoxifen therapy.
Treatment of advanced breast cancer in women with natural or induced postmenopausal status who have progression of the disease after anti-estrogen therapy. Efficacy has not been demonstrated in patients with a negative test for estrogen receptors.
Contraindications
Hypersensitivity to exemestane or to any other component of the drug;
premenopausal period;
During pregnancy and breastfeeding.
Recent Reviews